

# Slide 10: Ximelagatran (Exanta / oral direct thrombin inhibitor)

---

Initial Task: DILI


SMILES: CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)/C(=N\O)/N

---


## Ximelagatran (Exanta / oral direct thrombin inhibitor) - Optimization Results

---

### Optimization Path



**\*\*Initial Molecule\*\*** `CCOC(=O)CN[C@H]  
(C1CCCCC1)C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)/  
C(=N\O)/N`




**\*\*QED (Drug-likeness):\*\*** 0.1308 **\*\*Number of Blocks:\*\*** 3

► Show ADMET Scores

| Task   | Score    |
|--------|----------|
| AMES   | 0.720076 |
| BBBP   | 0.000080 |
| CYP3A4 | 0.018008 |
| DILI   | 0.649647 |
| HIA    | 0.997815 |
| PGP    | 0.655136 |

**\*\*Final Optimized\*\*** `CC(=O)OC[C@H](CON1CC[C@H]1C(=O)N1Cc2c(-  
c3ccc([C@@H](C)C(=O)O)cc3F)n[nH]c2C1(C)C)OC(C)=O`



**\*\*QED (Drug-likeness):\*\*** 0.4148 (+0.2840) ✓ **\*\*Number of Blocks:\*\*** 3 (+0) ➔  
**\*\*Total Block Changes:\*\*** 10

► Show ADMET Scores


| Task     | Score    | Change    | Rel. Improvement | % Change     |
|----------|----------|-----------|------------------|--------------|
| AMES ✓   | 0.404659 | -0.315416 | +0.4380          | -43.80%      |
| BBBP ✓   | 0.999947 | +0.999867 | +12529.0183      | +1252901.83% |
| CYP3A4 ✗ | 0.020061 | +0.002053 | -0.1140          | +11.40%      |
| DILI ✓   | 0.408363 | -0.241285 | +0.3714          | -37.14%      |
| HIA ✗    | 0.991177 | -0.006638 | -0.0067          | -0.67%       |
| PGP ✗    | 0.659510 | +0.004374 | -0.0067          | +0.67%       |

### Optimization Steps:

DETAILS PLACEHOLDER2

#### After (Step 1)

CCOC(=O)CN[C@H](C(=O)N1CC[C@H]1C(=O)OC[C@H](CCl)OC(C)=O)C1CCCCC1



**QED:** 0.2796 (+0.1488) ✓

**Number of Blocks:** 3 (+0) →


**Block Changes:** 2 (+1, -1)

**DILI Score:** 0.649647 → 0.419199 (-0.230448)


DETAILS *PLACEHOLDER3*

► Step 2: AMES (+0.3920 ↓) →

**\*\*Before (Step 1)\*\*** `CCOC(=O)CN[C@@H]  
(C(=O)N1CC[C@H]1C(=O)OC[C@@H](CCl)OC(C)=O)C1CCCCC1`



**\*\*After (Step 2)\*\*** `CCOC(=O)CN[C@@H]  
(C(=O)N1CC[C@H]1C(=O)N1Cc2c(-c3ccc(C)s3)n[nH]c2C1(C)C)C1CCCCC1`



**\*\*QED:\*\*** 0.2796 **\*\*Number of Blocks:\*\*** 3

#### ► All ADMET Scores

| Task   | Score    | Direction |
|--------|----------|-----------|
| AMES   | 0.340648 | ↓ lower   |
| BBBP   | 0.999998 | ↑ higher  |
| CYP3A4 | 0.025386 | ↓ lower   |
| DILI   | 0.419199 | ↓ lower   |
| HIA    | 0.999903 | ↑ higher  |
| PGP    | 0.814016 | ↓ lower   |

**QED:** 0.4934 (+0.2138)

**Number of Blocks:** 4 (+1) ↑

**Block Changes:** 3 (+2, -1)


**AMES Score:** 0.340648 → 0.732660 (+0.392012)

DETAILSPLACEHOLDER5

DETAILSPLACEHOLDER6

#### After (Step 3)

CC(=O)OC[C@H](CON1CC[C@H]1C(=O)N1Cc2c(-c3ccc([C@@H](C)C(=O)O)cc3F)n[nH]c2C1(C)C)OC(C)=O



**QED:** 0.4148 (-0.0787) ✗

**Number of Blocks:** 3 (-1) ↓

**Block Changes:** 5 (+2, -3)

**AMES Score:** 0.732660 → 0.404659 (-0.328000)

DETAILS PLACEHOLDER

## 📊 Step Details

### Step 1: DILI ✓

| Original | New      | Change      |
|----------|----------|-------------|
| 0.649647 | 0.419199 | -0.230448 ↓ |

CCOC(=O)CN[C@H](C(=O)N1CC[C@H]1C(=O)OC[C@H](CCl)OC(C)=O)C1CCCC1

### Step 2: AMES ⚠

| Original | New      | Change      |
|----------|----------|-------------|
| 0.340648 | 0.732660 | +0.392012 ↓ |

CCOC(=O)CN[C@H](C(=O)N1CC[C@H]1C(=O)N1Cc2c(-c3ccc(C)s3)n[nH]c2C1(C)C)C1CCCC1

### Step 3: AMES ✓

| Original | New      | Change      |
|----------|----------|-------------|
| 0.732660 | 0.404659 | -0.328000 ↓ |

CC(=O)OC[C@H](CON1CC[C@H]1C(=O)N1Cc2c(-c3ccc([C@@H](C)C(=O)O)cc3F)n[nH]c2C1(C)C)OC(C)=O

## ADMET Comparison

| Task   | Direction | Initial  | Final    | Change    | Rel. Improvement | % Change     | Status                  |
|--------|-----------|----------|----------|-----------|------------------|--------------|-------------------------|
| AMES   | ↓ lower   | 0.720076 | 0.404659 | -0.315416 | +0.4380          | -43.80%      | <span>✓ Improved</span> |
| BBBP   | ↑ higher  | 0.000080 | 0.999947 | +0.999867 | +12529.0183      | +1252901.83% | <span>✓ Improved</span> |
| CYP3A4 | ↓ lower   | 0.018008 | 0.020061 | +0.002053 | -0.1140          | +11.40%      | <span>✗ Declined</span> |
| DILI   | ↓ lower   | 0.649647 | 0.408363 | -0.241285 | +0.3714          | -37.14%      | <span>✓ Improved</span> |
| HIA    | ↑ higher  | 0.997815 | 0.991177 | -0.006638 | -0.0067          | -0.67%       | <span>✗ Declined</span> |
| PGP    | ↓ lower   | 0.655136 | 0.659510 | +0.004374 | -0.0067          | +0.67%       | <span>✗ Declined</span> |

**Improved:** 3/6 (50.0%) | **Molecules:** 283 | **Paths:** 3915

## 🔍 Safety Threshold Analysis

**Status:** 3/6 meet thresholds

⚠ Below threshold: 3

| Task | Score  | Threshold | Gap    |
|------|--------|-----------|--------|
| PGP  | 0.6595 | ↓ 0.3     | 0.3595 |
| AMES | 0.4047 | ↓ 0.3     | 0.1047 |
| DILI | 0.4084 | ↓ 0.4     | 0.0084 |

✓ Passing: 3

| Task   | Score  | Threshold |
|--------|--------|-----------|
| BBBP   | 0.9999 | ↑ 0.5     |
| CYP3A4 | 0.0201 | ↓ 0.55    |
| HIA    | 0.9912 | ↑ 0.2     |